CL2009000608A1 -
Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone from the first to the third phase decreases from 3 mg to 1.5 mg and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 placebo dosage units or no dosage units; pharmaceutical kit.
- Google Patents
Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone from the first to the third phase decreases from 3 mg to 1.5 mg and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 placebo dosage units or no dosage units; pharmaceutical kit.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=41665344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000608(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma AgfiledCriticalBayer Schering Pharma Ag
Publication of CL2009000608A1publicationCriticalpatent/CL2009000608A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Producto farmacéutico que comprende drospirenona y 17beta-estradiol, combinación que contiene este producto y kit que contiene esta combinación.Pharmaceutical product comprising drospirenone and 17beta-estradiol, combination that contains this product and kit that contains this combination.
CL2009000608A2008-03-132009-03-13
Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone from the first to the third phase decreases from 3 mg to 1.5 mg and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 placebo dosage units or no dosage units; pharmaceutical kit.
CL2009000608A1
(en)
Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone from the first to the third phase decreases from 3 mg to 1.5 mg and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 placebo dosage units or no dosage units; pharmaceutical kit.
USE OF A STROGEN FOR THE TREATMENT OF DISEASES, CONDITIONS OR SYMPTOMS ASSOCIATED WITH DEFICIENT LEVELS OF STROGENS IN A WOMAN; PHARMACEUTICAL COMPOSITION THAT INCLUDES DAILY DOSAGE UNITS OF ESTRADIOL HEMIDRATE> 0.75 AND 1
DERIVATIVES OF 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINA SUBSTITUTED WITH AMINOALCOHOLES THAT ARE USEFUL TO TREAT HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
Compounds derived from benzoxazepine condensed with pyrazolyl or imidazolyl, inhibitors of pi3 kinase activity; pharmaceutical composition comprising a compound; and its use in the preparation of drugs for the treatment of cancer.
COMPOUNDS DERIVED FROM 1-OXA-3-AZAESPIRO [4.5] DECAN-2-ONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF A FOOD, OBESITY, DEPRESSION DISORDER.
Derivatives of 1h-benzoimidazol-2-yl-propyl-methyl-amino-ethyl-5-aryl-bicyclo[2.2.2]oct-5-en-2-ol, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
COMPOUNDS DERIVED FROM 3-CYANOPIRIDINE, INHIBITORS OF THE P2Y12 RECEPTOR; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE DISORDER OF THE PLAQUETARY AGGREGATION.
Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone from the first to the third phase decreases from 3 mg to 1.5 mg and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 placebo dosage units or no dosage units; pharmaceutical kit.
Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone during the three phases is constant and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 dosage units of placebo or without units of dosage; pharmaceutical kit.